![](/images/2013/post-sep.jpg)
Chronic Hepatitis B Market Poised for $6.2 Billion by 2031, Driven by Diagnostic Advancements and Rising Infections
![The global market for chronic hepatitis B (CHB) was valued at $4 Chronic Hepatitis B (CHB) Market Size, Share](https://img.einnews.com/ampsize/737712/chronic-hepatitis-b-chb-marke.png)
Chronic Hepatitis B (CHB) Market Size, Share
PORTLAND, OR, UNITED STATES, September 10, 2024 /EINPresswire.com/ -- The global market for chronic hepatitis B (CHB) was valued at $4.6 billion in 2021 and is projected to grow to $6.2 billion by 2031, with a compound annual growth rate (CAGR) of 3% from 2022 to 2031. Hepatitis B is a viral infection that causes liver inflammation and, in some cases, leads to severe liver damage. The virus spreads primarily through contact with infected blood. Testing methods for hepatitis B include antibody tests, genotype tests, and viral load assessments. CHB treatment often involves antiviral drugs and immune modulators.
๐๐๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ
โข Cipla Ltd
โข Teva Pharmaceutical Industries Limited
โข Bristol Myers Squibb Co.
โข F. Hoffman La Roche
โข GlaxoSmithKline (GSK)
โข Viatris Inc. (Mylan NV)
โข Merck & Co. Inc.
โข Novartis AG
โข Gilead Sciences
โข zydus cadila
๐๐๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/A31523
Key Drivers of Market Growth
Several factors are contributing to the expansion of the CHB market:
1. Increased Blood Transfusion and Donation Rates: Blood transfusions are a key contributor to the transmission of hepatitis B, prompting mandatory hepatitis screening for blood donors. The rise in blood donation rates boosts the demand for diagnostic testing and contributes to the growth of the CHB market.
2. Rising Hepatitis B Cases: According to a 2022 report by the World Health Organization (WHO), about 296 million people were living with chronic hepatitis B in 2019, with 1.5 million new infections each year. This growing prevalence drives demand for CHB treatment and diagnosis, spurring market growth.
3. Advancements in Treatment: The market is experiencing robust growth due to innovations in CHB therapies. For example, Gilead Sciencesโ Hepcludex (bulevirtide) showed promising results in a Phase 3 clinical trial for treating hepatitis delta virus (HDV), further driving interest in advanced therapeutic solutions.
4. R&D and Product Launches: Increased research and development (R&D) activities in CHB treatments, especially for more affordable and effective solutions, are fueling the market. New product launches and approvals also boost growth by offering healthcare providers more options to treat the disease.
Market Segmentation
The chronic hepatitis B market is segmented based on drug class, gender, distribution channel, and region:
1. Drug Class:
โข The antivirals segment dominated the market in 2021 and is expected to maintain its leading position due to improvements in healthcare infrastructure and the prevalence of infectious diseases.
โข The immune modulators segment is expected to witness significant growth during the forecast period, driven by ongoing R&D efforts.
2. Gender:
โข The male segment held the largest market share in 2021, largely due to the higher prevalence of CHB among men.
โข The female segment is projected to see considerable growth, supported by the increasing number of female healthcare workers and rising healthcare spending.
3. Distribution Channel:
โข Drug stores and retail pharmacies dominated the market in 2021, reflecting rising accessibility and government investments in healthcare infrastructure.
โข The online providers segment is expected to grow significantly, driven by the convenience of online purchasing and an aging population in need of accessible healthcare solutions.
4. Regional Analysis:
โข North America held the largest share of the global CHB market in 2021, driven by a high incidence of chronic diseases, advanced healthcare infrastructure, and the presence of leading pharmaceutical companies.
โข Asia-Pacific is expected to see the most substantial growth, supported by a high population base, increasing cases of infectious diseases, and improvements in healthcare infrastructure.
Industry Growth Catalysts
Several factors are set to boost the CHB market over the coming years:
โข Diagnostic Improvements: The establishment of diagnostic centers and blood banks, coupled with WHO recommendations for mandatory screening of blood donations for hepatitis B and other infectious diseases, will drive the market.
โข Healthcare Expansion: Growth in hospital numbers, increased access to healthcare services, and rising healthcare expenditure will further support market expansion. According to the American Medical Association (AMA), U.S. healthcare spending surged by 9.7% in 2020, reaching $4.1 trillion.
โข Government Initiatives: Increased government investments in healthcare infrastructure and improved regulations on blood donations and healthcare standards will promote the marketโs growth, especially in regions with developing healthcare systems.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ฒ๐ข๐ง๐ : https://www.alliedmarketresearch.com/purchase-enquiry/A31523
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X
![](https://health.einnews.com/tracking/article.gif?aid=742199270§ion=einpresswire&a=UEjr3vgYPB6zI08B&i=FmByxSwPQ5ivEx-7)
Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release